186 related articles for article (PubMed ID: 9777974)
21. A review of nonclinical toxicology studies of becaplermin (rhPDGF-BB).
Knight EV; Oldham JW; Mohler MA; Liu S; Dooley J
Am J Surg; 1998 Aug; 176(2A Suppl):55S-60S. PubMed ID: 9777973
[TBL] [Abstract][Full Text] [Related]
22. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers.
Mustoe TA; Cutler NR; Allman RM; Goode PS; Deuel TF; Prause JA; Bear M; Serdar CM; Pierce GF
Arch Surg; 1994 Feb; 129(2):213-9. PubMed ID: 8304833
[TBL] [Abstract][Full Text] [Related]
23. Use of Regranex gel for diabetic foot ulcers.
Piascik P
J Am Pharm Assoc (Wash); 1998; 38(5):628-30. PubMed ID: 9782698
[No Abstract] [Full Text] [Related]
24. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study.
Guzman-Gardearzabal E; Leyva-Bohorquez G; Salas-Colín S; Paz-Janeiro JL; Alvarado-Ruiz R; García-Salazar R
Adv Ther; 2000; 17(4):184-9. PubMed ID: 11185057
[TBL] [Abstract][Full Text] [Related]
25. [Experimental study on recombinant human platelet-derived growth factor gel in a diabetic rat model of cutaneous incisal wound healing].
Sun TZ; Fu XB; Zhao ZL; Chen W; Sun XQ; Zhou G; Shen ZY
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Oct; 15(10):596-9. PubMed ID: 14552680
[TBL] [Abstract][Full Text] [Related]
26. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
Persson U; Willis M; Odegaard K; Apelqvist J
Value Health; 2000; 3 Suppl 1():39-46. PubMed ID: 16464208
[TBL] [Abstract][Full Text] [Related]
27. Role of platelet-derived growth factor as an adjunct to surgery in the management of pressure ulcers.
Kallianinen LK; Hirshberg J; Marchant B; Rees RS
Plast Reconstr Surg; 2000 Nov; 106(6):1243-8. PubMed ID: 11083552
[TBL] [Abstract][Full Text] [Related]
28. Platelet-rich plasma: support for its use in wound healing.
Lacci KM; Dardik A
Yale J Biol Med; 2010 Mar; 83(1):1-9. PubMed ID: 20351977
[TBL] [Abstract][Full Text] [Related]
29. Effect of platelet-derived growth factor-BB on bone formation in calvarial defects: an experimental study in rabbits.
Vikjaer D; Blom S; Hjørting-Hansen E; Pinholt EM
Eur J Oral Sci; 1997 Feb; 105(1):59-66. PubMed ID: 9085030
[TBL] [Abstract][Full Text] [Related]
30. Re: Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers.
Brown GL
Ann Plast Surg; 1993 Feb; 30(2):192. PubMed ID: 8489189
[No Abstract] [Full Text] [Related]
31. Platelet derived growth factor-BB levels in gingival crevicular fluid of localized intrabony defect sites treated with platelet rich fibrin membrane or collagen membrane containing recombinant human platelet derived growth factor-BB: A randomized clinical and biochemical study.
Joshi AA; Padhye AM; Gupta HS
J Periodontol; 2019 Jul; 90(7):701-708. PubMed ID: 30637748
[TBL] [Abstract][Full Text] [Related]
32. Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent.
Agren MS; Steenfos HH; Dabelsteen S; Hansen JB; Dabelsteen E
J Invest Dermatol; 1999 Apr; 112(4):463-9. PubMed ID: 10201530
[TBL] [Abstract][Full Text] [Related]
33. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis.
Landsman A; Agnew P; Parish L; Joseph R; Galiano RD
J Am Podiatr Med Assoc; 2010; 100(3):155-60. PubMed ID: 20479444
[TBL] [Abstract][Full Text] [Related]
34. Transfer of platelet-derived growth factor-BB gene by gene gun increases contraction of collagen lattice by fibroblasts in diabetic and non-diabetic human skin.
Kuwahara H; Mitchell AT; Macklin MD; Zhao J; Listengarten D; Phillips LG
Scand J Plast Reconstr Surg Hand Surg; 2000 Dec; 34(4):301-7. PubMed ID: 11195866
[TBL] [Abstract][Full Text] [Related]
35. Platelet-derived growth factor-BB accelerates wound closure in a new mesentery culture model without macrophages.
Wu L; Kumar SB; Porras-Reyes BH; Gramates PH; Mustoe TA
Ann Plast Surg; 1994 Aug; 33(2):155-61. PubMed ID: 7979047
[TBL] [Abstract][Full Text] [Related]
36. Human plasma fibronectin potentiates the mitogenic activity of platelet-derived growth factor and complements its wound healing effects.
Larivière B; Rouleau M; Picard S; Beaulieu AD
Wound Repair Regen; 2003; 11(1):79-89. PubMed ID: 12581430
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
[TBL] [Abstract][Full Text] [Related]
38. A fragment of secreted Hsp90α carries properties that enable it to accelerate effectively both acute and diabetic wound healing in mice.
Cheng CF; Sahu D; Tsen F; Zhao Z; Fan J; Kim R; Wang X; O'Brien K; Li Y; Kuang Y; Chen M; Woodley DT; Li W
J Clin Invest; 2011 Nov; 121(11):4348-61. PubMed ID: 22019588
[TBL] [Abstract][Full Text] [Related]
39. Growth factors and chronic wound healing: past, present, and future.
Goldman R
Adv Skin Wound Care; 2004; 17(1):24-35. PubMed ID: 14752324
[TBL] [Abstract][Full Text] [Related]
40. Influence of platelet-derived growth factor on microcirculation during normal and impaired wound healing.
Uhl E; Rösken F; Sirsjö A; Messmer K
Wound Repair Regen; 2003; 11(5):361-7. PubMed ID: 12950640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
